Clinical Trials
32 trialsBusulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial
Alliance for Clinical Trials in Oncology
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
CML0408
Gruppo Italiano Malattie EMatologiche dell'Adulto
Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Case Comprehensive Cancer Center
Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Cancer Trials Ireland
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
University of Kansas Medical Center
Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Biomarkers in DNA Samples From Patients With High-Risk Acute Lymphoblastic Leukemia
Children's Oncology Group
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
Children's Oncology Group
Biomarkers in DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin
Children's Oncology Group
Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia
Children's Oncology Group
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
Children's Oncology Group
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
Memorial Sloan Kettering Cancer Center
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
Memorial Sloan Kettering Cancer Center
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
City of Hope Medical Center
Biomarkers in Patients With Acute Myeloid Leukemia
Children's Oncology Group
S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia
SWOG Cancer Research Network
S9031-9333-0106-0112-A Study of Biomarkers in Samples From Patients With Acute Myeloid Leukemia Treated With Standard Chemotherapy With or Without Gemtuzumab Ozogamicin
SWOG Cancer Research Network
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant
Vanderbilt University
Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia
City of Hope Medical Center
Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome
Children's Oncology Group
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
National Cancer Institute (NCI)
Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant
National Cancer Institute (NCI)
Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
University of Glasgow
Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
Northwestern University
Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
National Cancer Institute (NCI)